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A heparin-like effect was recently described in infants,
children, and adults receiving bivalirudin while
supported on extracorporeal membrane oxygenation
following cardiopulmonary bypass. This is most likely
due to endogenous release of glycosaminoglycans
from vascular endothelium and mast cells and is
associated with longer duration of extracorporeal
membrane oxygenation and an increased incidence
of sepsis. Further investigation into this effect should
include patients without recent cardiopulmonary
bypass, exclude the presence of covalent
antithrombin-heparin complexes, and employ a variety
of different heparinases for thromboelastography. The
phenomenon may partially explain the heterogeneity
of anticoagulation requirements in patients on
extracorporeal life support.thors speculated that the HLE was due to release of nativeIntroduction
Extracorporeal membrane oxygenation (ECMO) has been
used for over 40 years in patients with refractory res-
piratory failure or shock. Over this time, there have been
continuous modifications and improvements in both the
circuitry and clinical management of ECMO. However,
one perennial problem has been the need to anticoagulate
blood passing through the circuit. Finding a balance be-
tween the risks of bleeding and clot formation is arguably
the most challenging problem in ECMO today, especially
in complex, vulnerable populations such as infants,
multitrauma patients, or when ECMO is deployed after
cardiopulmonary bypass (CPB). Unfractionated heparin
(UFH) remains the most commonly used anticoagulant* Correspondence: gmaclaren@iinet.net.au
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medium, for 12 months following its publicatio
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(http://creativecommons.org/publicdomain/zerofor ECMO. Heparin is a naturally occurring glycosamino-
glycan (GAG) that is usually bound to endothelium but
can be secreted into the bloodstream. Other GAGs,
including heparan sulphate, chondroitin sulphate, and
dermatan sulphate, are known to prolong anticoagulation
tests and thus exhibit a heparin-like effect (HLE), although
they are not usually used as therapeutic agents.Commentary
In this issue of Critical Care, Ranucci and colleagues [1]
demonstrate a novel phenomenon in a cohort of post-
cardiotomy patients receiving bivalirudin on ECMO. Based
on thromboelastography with and without heparinase, the
authors documented HLE in over half the cohort, even
although none of the patients received UFH after the con-
clusion of CPB. HLE was associated with a longer duration
of ECMO and an increased incidence of sepsis. The au-
heparinoids from the glycocalyx and mast cells.
There are many aspects to consider with these intri-
guing new findings. A variety of heparinases are commer-
cially available, but the specifics of the ones used in this
study were not provided, so it is unknown whether the
heparinase used was specific for cleaving heparin and
heparin sulphate or whether it cleaved a wider range of
GAGs such as dermatan or chondroitin sulphates. The
nature of the molecule causing the HLE thus remains to
be elucidated. The authors may be correct in their hypoth-
esis that GAGs released from the vascular endothelium
were responsible, but an increase in GAGs may also have
been secondary to increased production in other tissues
or because of inadequate hepatic clearance. It is equally
unclear whether they were released as a consequence of
sepsis or as a result of damaged endothelium which might
later render the patients more vulnerable to sepsis. In
other words, were GAGs the cause of the apparent differ-
ences in clinical outcome, a consequence, or completely
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what other reasons might explain the authors’ findings?
All of the patients in the study received UFH during
CPB. Given that the HLE was seen predominantly in the
first 7 days post-bypass, one possible explanation is that
there was a reservoir of heparin in an extravascular
compartment which later redistributed into the blood
after CPB was completed. In patients who have CPB
with UFH, there is often a rebound of measures of UFH
activity in the 24 hours following reversal with protam-
ine. However, after following a control group who were
not on ECMO, the authors found nothing to support
this hypothesis, so attributing HLE to heparin rebound
appears unlikely.
A more intriguing alternative is that the persistent
effect over the first week after CPB represented a residual
covalent antithrombin-heparin complex (ATH) formed
during the high-concentration UFH of CPB. ATH may
not be well reversed by protamine and is known to have a
very long half-life [2,3]. ATH most likely forms under the
conditions of CPB, but little research has been done to
establish how frequently or to what extent it occurs in
patients. A simple means of investigating this further
would be to repeat the study in patients who are on
ECMO for reasons unrelated to CPB, where no hep-
arin was used prior to ECMO. Alternatively, ATH
levels could be measured and correlated to the R-time on
thromboelastography.
This study has a number of limitations, which are
acknowledged by the authors. It was a small, retrospect-
ive, single-center study with an extremely heteroge-
neous population combining neonatal, pediatric, and
adult patients. A variety of ECMO machines were used,
the surface coatings of which can elicit different pa-
thophysiological responses from vascular endothelium.
Additionally, the study described neither where the
blood samples for the thromboelastography were taken
from nor whether the samples were taken from heparin-
ized lines, raising the possibility of heparin contamination.
Despite these limitations, it appears probable, given the
data presented, that the authors have demonstrated a
potentially important new finding with clinical implica-
tions that mandate further research.
Conclusions
The uncertainty surrounding optimal anticoagulation prac-
tices for ECMO was recently highlighted by the Extracor-
poreal Life Support Organization in its anticoagulation
guidelines [4]. Despite decades of research, the complex
interactions of coagulation and inflammation pathways
during ECMO are poorly understood. The findings, under-
lying hypotheses, and potential clinical implications of the
present study will be of interest to ECMO clinicians. Fur-
ther research from other centers and in non-CPB patientsis warranted to confirm whether the phenomenon is re-
producible and, if so, to determine the mechanism. A
hitherto undetected HLE might go a considerable way
toward explaining the heterogeneity of anticoagulation
requirements in ECMO patients. By elucidating the me-
chanism of HLE, we will not only learn more about
the pathophysiological role of GAGs in critical illness,
we may yet make anticoagulation in ECMO safer and
simpler.
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